<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537926</url>
  </required_header>
  <id_info>
    <org_study_id>HALT-HCM</org_study_id>
    <secondary_id>IR34HL105563</secondary_id>
    <nct_id>NCT01537926</nct_id>
  </id_info>
  <brief_title>Hypertrophic Regression With N-Acetylcysteine in HCM</brief_title>
  <acronym>HALT</acronym>
  <official_title>Pilot Feasibility Study With N-acetylcystein (NAC) in Patients With HCM Caused by Sarcomere Proteins Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the sudy is to conduct a small study to gather the preliminary data for future&#xD;
      lage scale clinical studies that will be designed test the potential beneficial effect of&#xD;
      over-the counter study anti-oxidant drug called N-acetylcysteine (NAC) in patients with a&#xD;
      heart muscle condition called Hypertrophic Cardiomyopathy (HCM). The present study is a pilot&#xD;
      feasibility study, the investigators want to find out whether the investigators can recruit&#xD;
      and retain patients with HCM in the study and whether these patients can tolerate this drug&#xD;
      and can stay on one year. Likewise, the investigators want to find out any potential side&#xD;
      effects that this drug might have and estimate whether it has any beneficial effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to perform a pilot study in patients with hypertrophic&#xD;
      cardiomyopathy (HCM) and mutations in genes encoding sarcomere proteins to assess safety and&#xD;
      gather the pre-requisite data for subsequent robust randomized placebo-controlled efficacy&#xD;
      studies with N-acetylcysteine (NAC). Data will be gathered on the recruitment, accrual,&#xD;
      retention, and compliance rates of HCM patients randomized to treatment with a placebo or two&#xD;
      escalating doses of NAC. Likewise, any potential side effects will be determined and the&#xD;
      effect size of NAC on indices of cardiac hypertrophy will be estimated. HCM, the main focus&#xD;
      of the study team's research during the past two decades, is the most common cause of sudden&#xD;
      cardiac death (SCD) in the young and an important cause of morbidity in the elderly. Despite&#xD;
      its clinical impact, there is no effective pharmacological therapy for HCM. None of the&#xD;
      current pharmacological therapies reverses or attenuates cardiac hypertrophy or reduces the&#xD;
      risk of SCD in adults. Cardiac hypertrophy, the quintessential clinical feature of human HCM,&#xD;
      is a major determinant of morbidity and the risk of SCD. Regression of cardiac hypertrophy is&#xD;
      expected to improve morbidity and decrease the risk of SCD in HCM, as observed upon&#xD;
      regression of load-dependent cardiac hypertrophy. The study team has generated transgenic&#xD;
      rabbit and mouse models of HCM and shown that cardiac hypertrophy and fibrosis could be&#xD;
      reversed through genetic or pharmacological interventions. Results with NAC, a precursor to&#xD;
      glutathione, the largest intracellular thiol pool against oxidative stress, were most&#xD;
      promising. In three independent studies in two different transgenic models of HCM (rabbits&#xD;
      and mouse), treatment with NAC completely reversed cardiac hypertrophy and fibrosis and&#xD;
      improved indices of diastolic function. The ultimate goal of every physician-scientist is to&#xD;
      apply the bench discoveries at the bedside. The study team proposes to test their findings in&#xD;
      the animal models in humans with HCM caused by sarcomere protein mutations. The use of NAC is&#xD;
      also supported by data showing increased oxidative stress in human HCM. Moreover, NAC has&#xD;
      been used extensively in humans and has a well-established safety profile. Resources&#xD;
      including patients with sarcomere protein mutations are available to successfully complete a&#xD;
      randomized placebo-controlled (N=25) pilot study to test two escalating doses of NAC (N=50),&#xD;
      administered for one year. The study aims to determine recruitment, accrual, retention and&#xD;
      compliance rates; tolerability, safety and side effects; and estimate the effect size of NAC&#xD;
      on the indices of cardiac hypertrophy at the baseline and after one year of treatment. Only&#xD;
      HCM patients with sarcomere proteins mutations will be included to exclude phenocopy. The&#xD;
      Core centers will interpret the phenotypic data to assure homogeneity. Data Coordinating&#xD;
      Center will assist in the research design, planning and conduct of the study and analysis of&#xD;
      the data. The findings will set the stage for large-scale robust randomized placebo-control&#xD;
      efficacy studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment as Assessed by Number of Participants Who Enrolled to the Study</measure>
    <time_frame>at the time of enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention as Assessed by Number of Participants Who Completed the Study</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance as Assessed by Percentage of Pills Taken by Participant</measure>
    <time_frame>from baseline to 12 months</time_frame>
    <description>Participants returned all pill bottles to the study team, and the number of pills not taken by the participant (that is, the number of pills remaining in the bottles) were counted. Compliance is reported as percentage of pills taken by the participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Side Effects Attributable to the Intervention</measure>
    <time_frame>from baseline to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Interventricular Septal Thickness (IVST) as Assessed by Echocardiography</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Interventricular Septal Thickness (IVST) as Assessed by Echocardiography</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End-systolic Diameter (LVESD) as Assessed by Echocardiography</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End-systolic Diameter (LVESD) as Assessed by Echocardiography</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass (LVM) as Assessed by Echocardiography</measure>
    <time_frame>baseline</time_frame>
    <description>Left Ventricular Mass (LVM) is the weight of the left heart and is estimated from the echocardiographic measurements that include left ventricular wall thickness and the chamber diameter. The weight is calculated in grams and then normalized to body surface area (m^2), with LVM reported as g/m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass (LVM) as Assessed by Echocardiography</measure>
    <time_frame>12 months</time_frame>
    <description>Left Ventricular Mass (LVM) is the weight of the left heart and is estimated from the echocardiographic measurements that include left ventricular wall thickness and the chamber diameter. The weight is calculated in grams and then normalized to body surface area (m^2), with LVM reported as g/m^2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine (NAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
    <arm_group_label>N-acetylcysteine (NAC)</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sugar pill manufactured to minic NAC 600mg capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary cardiac hypertrophy, non-dilated LV cavity and preserved LV&#xD;
             systolic function, hence, the diagnosis of HCM, who have at least an LV end diastolic&#xD;
             (LVSD) wall thickness of at least 15 mm on a 2D echocardiogram and&#xD;
&#xD;
          -  Known to have mutations in genes encoding sarcomeric proteins&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to NAC&#xD;
&#xD;
          -  Individuals younger than 18 years old (in the pilot study)&#xD;
&#xD;
          -  Phenocopy conditions, diagnosed clinically or genetically&#xD;
&#xD;
          -  Patients who have undergone transcatheter (alcohol) septal ablation within 6 months.&#xD;
&#xD;
          -  Individuals (typically family members) with causal mutations but an LVSD wall&#xD;
             thickness of &lt;15 mm&#xD;
&#xD;
          -  Patients with concomitant diseases such as:&#xD;
&#xD;
               -  Significant coronary artery disease &gt;70% luminal diameter stenosis in ny of the&#xD;
                  major coronary arteries (if known);&#xD;
&#xD;
               -  Valvular heart diseases (more than mild aortic stenosis and mitral regurgitation,&#xD;
                  the latter judged to be due to primary mitral valve abnormalities);&#xD;
&#xD;
               -  Uncontrolled hypertension, defined as systolic blood pressure of&#xD;
&#xD;
                    -  140 mmHg and diastolic blood pressure of â‰¥90 mmHg on medication, mean of&#xD;
                       three measurements at rest);&#xD;
&#xD;
               -  Other significant medical problems, such as moderate to severe chronic renal&#xD;
                  failure (GFR&lt;45 ml/min/1.73m2), advanced liver disease, cancer, or other&#xD;
                  disabling conditions&#xD;
&#xD;
          -  Pregnant women, nursing mothers and those who plan pregnancy during the study period&#xD;
&#xD;
          -  Those with active asthma (albeit the concern is relevant to nebulizer form but not&#xD;
             oral formulations)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali J. Marian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Marian AJ, Tan Y, Li L, Chang J, Syrris P, Hessabi M, Rahbar MH, Willerson JT, Cheong BY, Liu CY, Kleiman NS, Bluemke DA, Nagueh SF. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study. Circ Res. 2018 Apr 13;122(8):1109-1118. doi: 10.1161/CIRCRESAHA.117.312647. Epub 2018 Mar 14.</citation>
    <PMID>29540445</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <results_first_submitted>April 30, 2018</results_first_submitted>
  <results_first_submitted_qc>November 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Ali. J. Marian</investigator_full_name>
    <investigator_title>Professor , Cardiovascular Genetics, IMM</investigator_title>
  </responsible_party>
  <keyword>HALT</keyword>
  <keyword>HCM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine (NAC)</title>
          <description>N-acetylcysteine (NAC) 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to minic NAC 600mg capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-acetylcysteine (NAC)</title>
          <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to minic NAC 600mg capsule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="15.0"/>
                    <measurement group_id="B2" value="47.6" spread="15.1"/>
                    <measurement group_id="B3" value="49.15" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recruitment as Assessed by Number of Participants Who Enrolled to the Study</title>
        <time_frame>at the time of enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Recruitment as Assessed by Number of Participants Who Enrolled to the Study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retention as Assessed by Number of Participants Who Completed the Study</title>
        <time_frame>from baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Retention as Assessed by Number of Participants Who Completed the Study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Compliance as Assessed by Percentage of Pills Taken by Participant</title>
        <description>Participants returned all pill bottles to the study team, and the number of pills not taken by the participant (that is, the number of pills remaining in the bottles) were counted. Compliance is reported as percentage of pills taken by the participant.</description>
        <time_frame>from baseline to 12 months</time_frame>
        <population>Data are reported for participants for whom all pill bottles were returned to the study team. It was not known whether the returned bottles contained placebo or NAC; therefore, the data for both arms are reported together.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.&#xD;
OR&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance as Assessed by Percentage of Pills Taken by Participant</title>
          <description>Participants returned all pill bottles to the study team, and the number of pills not taken by the participant (that is, the number of pills remaining in the bottles) were counted. Compliance is reported as percentage of pills taken by the participant.</description>
          <population>Data are reported for participants for whom all pill bottles were returned to the study team. It was not known whether the returned bottles contained placebo or NAC; therefore, the data for both arms are reported together.</population>
          <units>percentage of pills taken</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="0.0878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Side Effects Attributable to the Intervention</title>
        <time_frame>from baseline to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Side Effects Attributable to the Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interventricular Septal Thickness (IVST) as Assessed by Echocardiography</title>
        <time_frame>baseline</time_frame>
        <population>Data are reported for all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Interventricular Septal Thickness (IVST) as Assessed by Echocardiography</title>
          <population>Data are reported for all participants who completed the study.</population>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.88" spread="4.59"/>
                    <measurement group_id="O2" value="18.00" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interventricular Septal Thickness (IVST) as Assessed by Echocardiography</title>
        <time_frame>12 months</time_frame>
        <population>Data are reported for all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Interventricular Septal Thickness (IVST) as Assessed by Echocardiography</title>
          <population>Data are reported for all participants who completed the study.</population>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.92" spread="3.3"/>
                    <measurement group_id="O2" value="17.82" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular End-systolic Diameter (LVESD) as Assessed by Echocardiography</title>
        <time_frame>12 months</time_frame>
        <population>Data are reported for all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End-systolic Diameter (LVESD) as Assessed by Echocardiography</title>
          <population>Data are reported for all participants who completed the study.</population>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.88" spread="5.29"/>
                    <measurement group_id="O2" value="21.55" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular End-systolic Diameter (LVESD) as Assessed by Echocardiography</title>
        <time_frame>baseline</time_frame>
        <population>Data are reported for all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End-systolic Diameter (LVESD) as Assessed by Echocardiography</title>
          <population>Data are reported for all participants who completed the study.</population>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.13" spread="6.06"/>
                    <measurement group_id="O2" value="22.64" spread="5.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Mass (LVM) as Assessed by Echocardiography</title>
        <description>Left Ventricular Mass (LVM) is the weight of the left heart and is estimated from the echocardiographic measurements that include left ventricular wall thickness and the chamber diameter. The weight is calculated in grams and then normalized to body surface area (m^2), with LVM reported as g/m^2.</description>
        <time_frame>baseline</time_frame>
        <population>Data are reported for all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Mass (LVM) as Assessed by Echocardiography</title>
          <description>Left Ventricular Mass (LVM) is the weight of the left heart and is estimated from the echocardiographic measurements that include left ventricular wall thickness and the chamber diameter. The weight is calculated in grams and then normalized to body surface area (m^2), with LVM reported as g/m^2.</description>
          <population>Data are reported for all participants who completed the study.</population>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.65" spread="94.17"/>
                    <measurement group_id="O2" value="292.80" spread="107.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Mass (LVM) as Assessed by Echocardiography</title>
        <description>Left Ventricular Mass (LVM) is the weight of the left heart and is estimated from the echocardiographic measurements that include left ventricular wall thickness and the chamber diameter. The weight is calculated in grams and then normalized to body surface area (m^2), with LVM reported as g/m^2.</description>
        <time_frame>12 months</time_frame>
        <population>Data are reported for all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine (NAC)</title>
            <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Mass (LVM) as Assessed by Echocardiography</title>
          <description>Left Ventricular Mass (LVM) is the weight of the left heart and is estimated from the echocardiographic measurements that include left ventricular wall thickness and the chamber diameter. The weight is calculated in grams and then normalized to body surface area (m^2), with LVM reported as g/m^2.</description>
          <population>Data are reported for all participants who completed the study.</population>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.98" spread="81.75"/>
                    <measurement group_id="O2" value="290.44" spread="99.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>N-acetylcysteine (NAC)</title>
          <description>N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.&#xD;
N-acetylcysteine: NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.&#xD;
Placebo: sugar pill manufactured to mimic NAC 600mg capsule</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Event was not related to administration of NAC.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <description>Event is not related to NAC.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small sample size of the study prohibits from making firm conclusions about efficacy of NAC in hypertrophic cardiomyopathy (HCM).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ali J. Marian</name_or_title>
      <organization>UTHealth Science Center at Houston</organization>
      <phone>713-500-2310</phone>
      <email>Ali.J.marian@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

